ClinicalTrials.gg
CompletedNCT06186622Updated May 22, 2026Results posted

A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants

A Phase 1 interventional study of Orforglipron and Simvastatin in Healthy, Obese and Overweight, sponsored by Eli Lilly and Company. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.

Enrollment
21st of 22
50 · median 324
Started
2024
with 5 others
Phase 1
6 of 22
none open now
Registered
9th of 22
by date
Lead sponsor
21 of 22
Eli Lilly and Company

Among the 22 studies testing orforglipron in Obesity, this one is the 21st largest by enrollment, is one of 6 that started in 2024, is one of 6 in phase 1, and was the 9th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing orforglipron in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to determine effect of orforglipron capsule formulation on the amount of digoxin, rosuvastatin, acetaminophen, midazolam, and simvastatin (each given alone and together with orforglipron) that enters the bloodstream and how long it takes the body to eliminate them when administered orally in healthy overweight and obese participants. In addition, the effect of the orforglipron tablet on the amount of simvastatin that enters the bloodstream and how long it takes the body to eliminate it will be evaluated.

The study will also assess the effect of sodium bicarbonate when administered alone with simvastatin versus orforglipron capsule containing sodium bicarbonate administered with simvastatin. The safety and tolerability of orforglipron and information about any side effects experienced will be collected.

Study will be conducted in two parts, with part 1 and 2 lasting up to approximately 23 and 24 weeks each, including the screening period.

03

Conditions studied

  • Healthy
  • Obese
  • Overweight
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical history and physical examination.
  • Have (BMI) equal to or greater than 27 kilograms per meter squared (kg/m²), inclusive, at screening.
  • Have an estimated equal to or greater than 60 milliliters per minute (mL/min).
  • Males and females who agree to follow requirements, or women not of (WNOCBP).
  • Have venous access sufficient to allow for blood sampling.

Exclusion criteria

Exclusion Criteria:

  • Have any type of diabetes with (HbA1c) level of 6.5 percent (%) or greater.
  • Have significant history of or currently have Major Depressive Disorder or psychiatric disorder within the last 2 years.
  • Obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome.
  • Have known gastric emptying abnormality.
  • Have undergone bariatric surgery (for example: Lap-Band, Gastric Bypass)
  • Have a known self or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or any form of thyroid cancer.
  • Have an abnormal 12-lead (ECG) at screening.
  • Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drug.
  • Participants must not be currently participating in or completed a clinical trial within the last 90 days.
  • Have a known allergy or to midazolam, simvastatin, rosuvastatin, or digoxin.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Cohort 1: Oral Drug Dosing With or Without Orforglipron Co-Administration

    Participants received single oral doses as follows:Day 1: 20 milligram(mg) simvastatin; Day 2: 0.25 mg digoxin; Day 7:20 mg simvastatin + 600 mg sodium bicarbonate; Day 8: 20 mg rosuvastatin; Day 10: 1000 mg acetaminophen; Day 12: 0.2 mg midazolam;Day 14: 1 mg Orforglipron, followed by 1000 mg acetaminophen administered 2 hours (±10 minutes) later (staggered); Day 15: 1 mg Orforglipron; Days 16-97: Orforglipron administered once daily with dose escalation every 14 days:1 mg (Days 16-27), 3 mg (Days 28-41),6 mg (Days 42-55),12 mg (Days 56-69),24 mg (Days 70-83),36 mg (Days 84-97). Days 98-110: 36 mg Orforglipron administered once daily with co administration as follows:Day 98: 20 mg simvastatin (simultaneous); Day 99: 0.25 mg digoxin (simultaneous); Day 104: 20 mg simvastatin (staggered); Day 105:20 mg rosuvastatin (simultaneous); Day 107: 1000 mg acetaminophen (staggered); Day 109:0.2 mg midazolam (simultaneous); Day 111: 20 mg Orforglipron tablet + 20 mg simvastatin (simultaneous).

    Drug: Orforglipron · Drug: Simvastatin · Drug: Digoxin · Drug: Rosuvastatin · Drug: Acetaminophen · Drug: Midazolam · Drug: Sodium Bicarbonate

  • Experimental
    Cohort 2: Oral Drug Dosing With or Without Orforglipron Co-Administration

    Participants received single oral doses as follows: Day 1: 20 mg Simvastatin; Day 2: 0.25 mg Digoxin; Day 7: 20 mg Simvastatin + 600 mg Sodium Bicarbonate; Day 9: 1 mg Orforglipron capsule; Days 10-90: Participants received orforglipron capsule orally QD for 12 weeks, beginning at 1 mg QD. The dose was escalated every 14 days as follows: 1 mg (Days 10-22), 3 mg (Days 23-36), 6 mg (Days 37-50), 12 mg (Days 51-64), 24 mg (Days 65-78), and 36 mg (Days 79-90). Participants continued 36 mg Orforglipron QD until Day 100, with co-administration of the following drugs; Day 93: 20 mg Simvastatin (simultaneous); Day 94: 0.25 mg Digoxin (simultaneous); Day 99: 20 mg Simvastatin administered 2 hours ±10 minutes after Orforglipron administration (staggered dosing); Day 101: 20 mg Orforglipron tablet + 20 mg Simvastatin (simultaneous)

    Drug: Orforglipron · Drug: Simvastatin · Drug: Digoxin · Drug: Sodium Bicarbonate

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC[0-∞]) of Simvastatin and Its Metabolite Simvastatin Acid Following Simultaneous Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)

    AUC \[0-∞\] of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without Orforglipron capsule were reported in this outcome measure.

    Time frame: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours (h) post-dose; Day 98 (Cohort 1) and Day 93 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose

  2. PK: AUC [0-∞] of Simvastatin and Its Metabolite Simvastatin Acid Following Staggered Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)

    AUC \[0-∞\] of simvastatin and its active acid metabolite (simvastatin acid) following staggered administration with or without Orforglipron capsule were reported in this outcome measure. Simvastatin was administered \~2h (±10 min) after Orforglipron capsule administration (Staggered dosing).

    Time frame: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 104 (Cohort 1) and Day 99 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose

  3. PK: AUC [0-∞] of Simvastatin and Its Metabolite Simvastatin Acid After Sodium Bicarbonate Coadministration (Cohort 1 and 2)

    AUC \[0-∞\] of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without sodium bicarbonate administration were reported in this outcome measure.

    Time frame: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 7 (Cohort 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose

  4. PK: AUC [0-∞] of Digoxin (Cohort 1 and 2)

    Time frame: Day 2 (For Cohort 1 and 2): Pre-dose, 0.5, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120h post-dose ; Day 99 (Cohort 1) and Day 94 (Cohort 2): Pre-dose, 0.5, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120h post-dose

  5. PK: AUC [0-∞] of Rosuvastatin (Cohort 1 Only)

    Time frame: Day 8 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dose; Day 105 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dose

  6. PK: AUC [0-∞] of Acetaminophen (Cohort 1 Only)

    AUC \[0-∞\] of acetaminophen following staggered administration with or without either 1 mg or 36 mg Orforglipron capsule were reported in this outcome measure. Acetaminophen was administered \~2h (±10 min) after Orforglipron capsule administration (Staggered dosing).

    Time frame: Day 10 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose; Day 14 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose; Day 107 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose

  7. PK: AUC [0-∞] of Midazolam and Its Metabolite 1'-Hydroxymidazolam (Cohort 1 Only)

    AUC \[0-∞\] of midazolam and its metabolite (1'-Hydroxymidazolam) following simultaneous administration with or without Orforglipron capsule were reported in this outcome measure.

    Time frame: Day 12 (Cohort 1 only): Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24h post-dose; Day 109 (Cohort 1 only): Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24h post-dose

  8. PK: Maximum Observed Concentration (Cmax) of Simvastatin and Its Metabolite Simvastatin Acid Following Simultaneous Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)

    Cmax of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without Orforglipron capsule were reported in this outcome measure.

    Time frame: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 98 (Cohort 1) and Day 93 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose

  9. PK: Cmax of Simvastatin and Its Metabolite Simvastatin Acid Following Staggered Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)

    Cmax of simvastatin and its active acid metabolite (simvastatin acid) following staggered administration with or without Orforglipron capsule were reported in this outcome measure. Simvastatin was administered \~2h (±10 min) after Orforglipron capsule administration (Staggered dosing).

    Time frame: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 104 (Cohort 1) and Day 99 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose

  10. PK: Cmax of Simvastatin and Its Metabolite Simvastatin Acid After Sodium Bicarbonate Coadministration (Cohort 1 and 2)

    Cmax of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without sodium bicarbonate administration were reported in this outcome measure.

    Time frame: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 7 (Cohort 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose

  11. PK: Cmax of Digoxin (Cohorts 1 and 2)

    Time frame: Day 2 (For Cohort 1 and 2): Pre-dose, 0.5, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120h post-dose; Day 99 (Cohort 1) and Day 94 (Cohort 2): Pre-dose, 0.5, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120h post-dose

  12. PK: Cmax of Rosuvastatin (Cohort 1 Only)

    Time frame: Day 8 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dose; Day 105 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dose

  13. PK: Cmax of Acetaminophen (Cohort 1 Only)

    Cmax of acetaminophen following staggered administration with or without either 1 mg or 36 mg Orforglipron capsule were reported in this outcome measure. Acetaminophen was administered \~2h (±10 min) after Orforglipron capsule administration (Staggered dosing).

    Time frame: Day 10 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose; Day 14 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose; Day 107 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose

  14. PK: Cmax of Midazolam and Its Metabolite 1'-Hydroxymidazolam (Cohort 1 Only)

    Cmax of Midazolam and its metabolite (1'-Hydroxymidazolam) following simultaneous administration with or without Orforglipron capsule is reported in this outcome measure.

    Time frame: Day 12 (Cohort 1 only): Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24h post-dose; Day 109 (Cohort 1 only): Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24h post-dose

Secondary outcomes

  1. PK: AUC [0-∞] of Simvastatin and Its Metabolite Simvastatin Acid Following Administration of Orforglipron Tablet Formulation (Cohort 1 and 2)

    AUC \[0-∞\] of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without Orforglipron tablet were reported in this outcome measure.

    Time frame: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 111 (Cohort 1) and Day 101 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose

  2. PK: Cmax of Simvastatin and Its Metabolite Simvastatin Acid Following Administration of Orforglipron Tablet Formulation (Cohort 1 and 2)

    Cmax of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without Orforglipron tablet were reported in this outcome measure.

    Time frame: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 111 (Cohort 1) and Day 101 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose

07

Results

Posted May 22, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: Oral Drug Dosing With or Without Orforglipron Co-AdministrationCohort 2: Oral Drug Dosing With or Without Orforglipron Co-Administration
Started3020
Safety analysis population (received at least one dose of study drug)3020
Completed2216
Not completed84
Withdrew: Adverse event61
Withdrew: Sponsor decision02
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC[0-∞]) of Simvastatin and Its Metabolite Simvastatin Acid Following Simultaneous Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)

AUC \[0-∞\] of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without Orforglipron capsule were reported in this outcome measure.

Time frame:
Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours (h) post-dose; Day 98 (Cohort 1) and Day 93 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose
Reported as:
Geometric mean · Nanogram* hours per milliliter (ng*h/ml)
Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC[0-∞]) of Simvastatin and Its Metabolite Simvastatin Acid Following Simultaneous Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)
Nanogram* hours per milliliter (ng*h/ml)20 mg Simvastatin AloneSimultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin
Simvastatin22.1 ± 79.218.8 ± 84.3
Metabolite- Simvastatin Acid13.6 ± 79.723.3 ± 74.2
PrimaryPK: AUC [0-∞] of Simvastatin and Its Metabolite Simvastatin Acid Following Staggered Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)

AUC \[0-∞\] of simvastatin and its active acid metabolite (simvastatin acid) following staggered administration with or without Orforglipron capsule were reported in this outcome measure. Simvastatin was administered \~2h (±10 min) after Orforglipron capsule administration (Staggered dosing).

Time frame:
Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 104 (Cohort 1) and Day 99 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose
Reported as:
Geometric mean · ng*h/ml
PK: AUC [0-∞] of Simvastatin and Its Metabolite Simvastatin Acid Following Staggered Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)
ng*h/ml20 mg Simvastatin AloneStaggered 36 mg Orforglipron Capsule + 20 mg Simvastatin
Simvastatin22.1 ± 79.220.1 ± 76.5
Metabolite- Simvastatin Acid13.6 ± 79.730.2 ± 70.3
PrimaryPK: AUC [0-∞] of Simvastatin and Its Metabolite Simvastatin Acid After Sodium Bicarbonate Coadministration (Cohort 1 and 2)

AUC \[0-∞\] of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without sodium bicarbonate administration were reported in this outcome measure.

Time frame:
Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 7 (Cohort 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose
Reported as:
Geometric mean · ng*h/ml
PK: AUC [0-∞] of Simvastatin and Its Metabolite Simvastatin Acid After Sodium Bicarbonate Coadministration (Cohort 1 and 2)
ng*h/ml20 mg Simvastatin Alone20 mg Simultaneous Simvastatin + 600 mg Sodium Bicarbonate
Simvastatin22.1 ± 79.220.3 ± 82.8
Metabolite- Simvastatin Acid13.6 ± 79.714.0 ± 61.3
PrimaryPK: AUC [0-∞] of Digoxin (Cohort 1 and 2)
Time frame:
Day 2 (For Cohort 1 and 2): Pre-dose, 0.5, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120h post-dose ; Day 99 (Cohort 1) and Day 94 (Cohort 2): Pre-dose, 0.5, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120h post-dose
Reported as:
Geometric mean · ng*h/ml
PK: AUC [0-∞] of Digoxin (Cohort 1 and 2)
ng*h/ml0.25 mg Digoxin AloneSimultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin
PK: AUC [0-∞] of Digoxin (Cohort 1 and 2)18.8 ± 21.522.4 ± 26.5
PrimaryPK: AUC [0-∞] of Rosuvastatin (Cohort 1 Only)
Time frame:
Day 8 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dose; Day 105 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dose
Reported as:
Geometric mean · ng*h/ml
PK: AUC [0-∞] of Rosuvastatin (Cohort 1 Only)
ng*h/ml20 mg Rosuvastatin AloneSimultaneous 36 mg Orforglipron Capsule + 20 mg Rosuvastatin
PK: AUC [0-∞] of Rosuvastatin (Cohort 1 Only)116 ± 52.1192 ± 60.1
PrimaryPK: AUC [0-∞] of Acetaminophen (Cohort 1 Only)

AUC \[0-∞\] of acetaminophen following staggered administration with or without either 1 mg or 36 mg Orforglipron capsule were reported in this outcome measure. Acetaminophen was administered \~2h (±10 min) after Orforglipron capsule administration (Staggered dosing).

Time frame:
Day 10 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose; Day 14 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose; Day 107 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose
Reported as:
Geometric mean · ng*h/ml
PK: AUC [0-∞] of Acetaminophen (Cohort 1 Only)
ng*h/ml1000 mg Acetaminophen AloneStaggered 1 mg Orforglipron Capsule + 1000 mg AcetaminophenStaggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen
PK: AUC [0-∞] of Acetaminophen (Cohort 1 Only)59900 ± 37.252900 ± 39.073000 ± 64.3
PrimaryPK: AUC [0-∞] of Midazolam and Its Metabolite 1'-Hydroxymidazolam (Cohort 1 Only)

AUC \[0-∞\] of midazolam and its metabolite (1'-Hydroxymidazolam) following simultaneous administration with or without Orforglipron capsule were reported in this outcome measure.

Time frame:
Day 12 (Cohort 1 only): Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24h post-dose; Day 109 (Cohort 1 only): Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24h post-dose
Reported as:
Geometric mean · ng*h/ml
PK: AUC [0-∞] of Midazolam and Its Metabolite 1'-Hydroxymidazolam (Cohort 1 Only)
ng*h/ml0.2 mg Midazolam AloneSimultaneous 36 mg Orforglipron Capsule + 0.2 mg Midazolam
Midazolam3.82 ± 41.24.60 ± 47.3
Metabolite- 1'-Hydroxymidazolam1.00 ± 43.21.34 ± 48.5
PrimaryPK: Maximum Observed Concentration (Cmax) of Simvastatin and Its Metabolite Simvastatin Acid Following Simultaneous Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)

Cmax of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without Orforglipron capsule were reported in this outcome measure.

Time frame:
Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 98 (Cohort 1) and Day 93 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose
Reported as:
Geometric mean · Nanogram per milliliter (ng/ml)
PK: Maximum Observed Concentration (Cmax) of Simvastatin and Its Metabolite Simvastatin Acid Following Simultaneous Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)
Nanogram per milliliter (ng/ml)20 mg Simvastatin AloneSimultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin
Simvastatin4.68 ± 80.34.07 ± 89.1
Metabolite-Simvastatin Acid1.25 ± 74.62.72 ± 84.8
PrimaryPK: Cmax of Simvastatin and Its Metabolite Simvastatin Acid Following Staggered Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)

Cmax of simvastatin and its active acid metabolite (simvastatin acid) following staggered administration with or without Orforglipron capsule were reported in this outcome measure. Simvastatin was administered \~2h (±10 min) after Orforglipron capsule administration (Staggered dosing).

Time frame:
Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 104 (Cohort 1) and Day 99 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose
Reported as:
Geometric mean · ng/ml
PK: Cmax of Simvastatin and Its Metabolite Simvastatin Acid Following Staggered Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)
ng/ml20 mg Simvastatin AloneStaggered 36 mg Orforglipron Capsule + 20 mg Simvastatin
Simvastatin4.68 ± 80.33.34 ± 82.7
Metabolite- Simvastatin Acid1.25 ± 74.62.94 ± 70.2
PrimaryPK: Cmax of Simvastatin and Its Metabolite Simvastatin Acid After Sodium Bicarbonate Coadministration (Cohort 1 and 2)

Cmax of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without sodium bicarbonate administration were reported in this outcome measure.

Time frame:
Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 7 (Cohort 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose
Reported as:
Geometric mean · ng/ml
PK: Cmax of Simvastatin and Its Metabolite Simvastatin Acid After Sodium Bicarbonate Coadministration (Cohort 1 and 2)
ng/ml20 mg Simvastatin Alone20 mg Simultaneous Simvastatin + 600 mg Sodium Bicarbonate
Simvastatin4.68 ± 80.34.62 ± 69.0
Metabolite- Simvastatin Acid1.25 ± 74.61.23 ± 67.2
PrimaryPK: Cmax of Digoxin (Cohorts 1 and 2)
Time frame:
Day 2 (For Cohort 1 and 2): Pre-dose, 0.5, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120h post-dose; Day 99 (Cohort 1) and Day 94 (Cohort 2): Pre-dose, 0.5, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120h post-dose
Reported as:
Geometric mean · ng/ml
PK: Cmax of Digoxin (Cohorts 1 and 2)
ng/ml0.25 mg Digoxin AloneSimultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin
PK: Cmax of Digoxin (Cohorts 1 and 2)1.02 ± 26.11.20 ± 46.1
PrimaryPK: Cmax of Rosuvastatin (Cohort 1 Only)
Time frame:
Day 8 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dose; Day 105 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dose
Reported as:
Geometric mean · ng/ml
PK: Cmax of Rosuvastatin (Cohort 1 Only)
ng/ml20 mg Rosuvastatin AloneSimultaneous 36 mg Orforglipron Capsule + 20 mg Rosuvastatin
PK: Cmax of Rosuvastatin (Cohort 1 Only)11.4 ± 69.814.2 ± 83.3
PrimaryPK: Cmax of Acetaminophen (Cohort 1 Only)

Cmax of acetaminophen following staggered administration with or without either 1 mg or 36 mg Orforglipron capsule were reported in this outcome measure. Acetaminophen was administered \~2h (±10 min) after Orforglipron capsule administration (Staggered dosing).

Time frame:
Day 10 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose; Day 14 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose; Day 107 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose
Reported as:
Geometric mean · ng/ml
PK: Cmax of Acetaminophen (Cohort 1 Only)
ng/ml1000 mg Acetaminophen AloneStaggered 1 mg Orforglipron Capsule + 1000 mg AcetaminophenStaggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen
PK: Cmax of Acetaminophen (Cohort 1 Only)10800 ± 29.57760 ± 42.210800 ± 57.7
PrimaryPK: Cmax of Midazolam and Its Metabolite 1'-Hydroxymidazolam (Cohort 1 Only)

Cmax of Midazolam and its metabolite (1'-Hydroxymidazolam) following simultaneous administration with or without Orforglipron capsule is reported in this outcome measure.

Time frame:
Day 12 (Cohort 1 only): Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24h post-dose; Day 109 (Cohort 1 only): Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24h post-dose
Reported as:
Geometric mean · ng/ml
PK: Cmax of Midazolam and Its Metabolite 1'-Hydroxymidazolam (Cohort 1 Only)
ng/ml0.2 mg Midazolam AloneSimultaneous 36 mg Orforglipron Capsule + 0.2 mg Midazolam
Midazolam1.23 ± 36.11.33 ± 43.8
Metabolite- 1'-Hydroxymidazolam0.331 ± 46.80.357 ± 54.6
SecondaryPK: AUC [0-∞] of Simvastatin and Its Metabolite Simvastatin Acid Following Administration of Orforglipron Tablet Formulation (Cohort 1 and 2)

AUC \[0-∞\] of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without Orforglipron tablet were reported in this outcome measure.

Time frame:
Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 111 (Cohort 1) and Day 101 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose
Reported as:
Geometric mean · ng*h/ml
PK: AUC [0-∞] of Simvastatin and Its Metabolite Simvastatin Acid Following Administration of Orforglipron Tablet Formulation (Cohort 1 and 2)
ng*h/ml20 mg Simvastatin AloneSimultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin
Simvastatin22.1 ± 79.221.0 ± 82.2
Metabolite- Simvastatin Acid13.6 ± 79.729.3 ± 72.0
SecondaryPK: Cmax of Simvastatin and Its Metabolite Simvastatin Acid Following Administration of Orforglipron Tablet Formulation (Cohort 1 and 2)

Cmax of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without Orforglipron tablet were reported in this outcome measure.

Time frame:
Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 111 (Cohort 1) and Day 101 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dose
Reported as:
Geometric mean · ng/ml
PK: Cmax of Simvastatin and Its Metabolite Simvastatin Acid Following Administration of Orforglipron Tablet Formulation (Cohort 1 and 2)
ng/ml20 mg Simvastatin AloneSimultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin
Simvastatin4.68 ± 80.33.78 ± 73.6
Metabolite- Simvastatin Acid1.25 ± 74.63.00 ± 67.9

Adverse events

Collected over Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: 20 mg Simvastatin Alone (Day 1)0/30 (0%)0/30 (0%)2/30 (6.7%)
Cohort 1: 0.25 mg Digoxin Alone (Day 2)0/30 (0%)0/30 (0%)0/30 (0%)
Cohort 1: 20 mg Simvastatin + 600 mg Sodium Bicarbonate (Day 7)0/28 (0%)0/28 (0%)0/28 (0%)
Cohort 1: 20 mg Rosuvastatin Alone (Day 8)0/28 (0%)0/28 (0%)0/28 (0%)
Cohort 1: 1000 mg Acetaminophen Alone (Day 10)0/27 (0%)0/27 (0%)1/27 (3.7%)
Cohort 1: 0.2 mg Midazolam Alone (Day 12)0/27 (0%)0/27 (0%)0/27 (0%)
Cohort 1: Staggered 1 mg Orforglipron Capsule + 1000 mg Acetaminophen (Day 14)0/27 (0%)0/27 (0%)1/27 (3.7%)
Cohort 1: 1 mg Orforglipron Capsule QD (Day 15 to Day 27)0/27 (0%)0/27 (0%)4/27 (14.8%)
Cohort 1: 3 mg Orforglipron Capsule QD (Day 28 to Day 41)0/26 (0%)0/26 (0%)2/26 (7.7%)
Cohort 1: 6 mg Orforglipron Capsule QD (Day 42 to Day 55)0/26 (0%)0/26 (0%)5/26 (19.2%)
Cohort 1: 12 mg Orforglipron Capsule QD (Day 56 to Day 69)0/26 (0%)0/26 (0%)2/26 (7.7%)
Cohort 1: 24 mg Orforglipron Capsule QD (Day 70 to Day 83)0/26 (0%)0/26 (0%)2/26 (7.7%)
Cohort 1: 36 mg Orforglipron Capsule QD (Day 84 to Day 97)0/26 (0%)0/26 (0%)11/26 (42.3%)
Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 98)0/22 (0%)0/22 (0%)0/22 (0%)
Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin (Day 99)0/22 (0%)0/22 (0%)2/22 (9.1%)
Cohort 1: 36 mg Orforglipron Capsule QD (Day 100 to Day 103)0/22 (0%)0/22 (0%)2/22 (9.1%)
Cohort 1: Staggered 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 104)0/22 (0%)0/22 (0%)0/22 (0%)
Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 20 mg Rosuvastatin (Day 105)0/22 (0%)0/22 (0%)2/22 (9.1%)
Cohort 1: 36 mg Orforglipron Capsule (Day 106)0/22 (0%)0/22 (0%)2/22 (9.1%)
Cohort 1: Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen (Day 107)0/22 (0%)0/22 (0%)1/22 (4.5%)
Cohort 1: 36 mg Orforglipron Capsule (Day 108)0/22 (0%)0/22 (0%)1/22 (4.5%)
Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 0.2 mg Midazolam (Day 109)0/21 (0%)0/21 (0%)1/21 (4.8%)
Cohort 1: 36 mg Orforglipron Capsule (Day 110)0/22 (0%)0/22 (0%)0/22 (0%)
Cohort 1: Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin (Day 111)0/22 (0%)0/22 (0%)2/22 (9.1%)
Cohort 2: 20 mg Simvastatin Alone (Day 1)0/20 (0%)0/20 (0%)1/20 (5%)
Cohort 2: 0.25 mg Digoxin Alone (Day 2)0/20 (0%)0/20 (0%)0/20 (0%)
Cohort 2: Simultaneous 20 mg Simvastatin + 600 mg Sodium Bicarbonate (Day 7)0/20 (0%)0/20 (0%)0/20 (0%)
Cohort 2: 1 mg Orforglipron Capsule QD (Day 9 to Day 22)0/20 (0%)0/20 (0%)9/20 (45%)
Cohort 2: 3 mg Orforglipron Capsule QD (Day 23 to Day 36)0/20 (0%)0/20 (0%)7/20 (35%)
Cohort 2: 6 mg Orforglipron Capsule QD (Day 37 to Day 50)0/19 (0%)0/19 (0%)6/19 (31.6%)
Cohort 2: 12 mg Orforglipron Capsule QD (Day 51 to Day 64)0/19 (0%)1/19 (5.3%)6/19 (31.6%)
Cohort 2: 24 mg Orforglipron Capsule QD (Day 65 to Day 78)0/18 (0%)0/18 (0%)4/18 (22.2%)
Cohort 2: 36 mg Orforglipron Capsule QD (Day 79 to Day 92)0/18 (0%)0/18 (0%)10/18 (55.6%)
Cohort 2: Simultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 93)0/16 (0%)0/16 (0%)1/16 (6.3%)
Cohort 2: Simultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin (Day 94)0/16 (0%)0/16 (0%)1/16 (6.3%)
Cohort 2: 36 mg Orforglipron Capsule QD (Day 95 to Day 98)0/16 (0%)0/16 (0%)2/16 (12.5%)
Cohort 2: Staggered 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 99)0/16 (0%)0/16 (0%)1/16 (6.3%)
Cohort 2: 36 mg Orforglipron Capsule (Day 100)0/16 (0%)0/16 (0%)0/16 (0%)
Cohort 2: Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin (Day 101)0/16 (0%)0/16 (0%)3/16 (18.8%)
Most frequent serious events
Most frequent serious events
EventCohort 1: 20 mg Simvastatin Alone (Day 1)Cohort 1: 0.25 mg Digoxin Alone (Day 2)Cohort 1: 20 mg Simvastatin + 600 mg Sodium Bicarbonate (Day 7)Cohort 1: 20 mg Rosuvastatin Alone (Day 8)Cohort 1: 1000 mg Acetaminophen Alone (Day 10)Cohort 1: 0.2 mg Midazolam Alone (Day 12)Cohort 1: Staggered 1 mg Orforglipron Capsule + 1000 mg Acetaminophen (Day 14)Cohort 1: 1 mg Orforglipron Capsule QD (Day 15 to Day 27)Cohort 1: 3 mg Orforglipron Capsule QD (Day 28 to Day 41)Cohort 1: 6 mg Orforglipron Capsule QD (Day 42 to Day 55)Cohort 1: 12 mg Orforglipron Capsule QD (Day 56 to Day 69)Cohort 1: 24 mg Orforglipron Capsule QD (Day 70 to Day 83)Cohort 1: 36 mg Orforglipron Capsule QD (Day 84 to Day 97)Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 98)Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin (Day 99)Cohort 1: 36 mg Orforglipron Capsule QD (Day 100 to Day 103)Cohort 1: Staggered 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 104)Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 20 mg Rosuvastatin (Day 105)Cohort 1: 36 mg Orforglipron Capsule (Day 106)Cohort 1: Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen (Day 107)Cohort 1: 36 mg Orforglipron Capsule (Day 108)Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 0.2 mg Midazolam (Day 109)Cohort 1: 36 mg Orforglipron Capsule (Day 110)Cohort 1: Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin (Day 111)Cohort 2: 20 mg Simvastatin Alone (Day 1)Cohort 2: 0.25 mg Digoxin Alone (Day 2)Cohort 2: Simultaneous 20 mg Simvastatin + 600 mg Sodium Bicarbonate (Day 7)Cohort 2: 1 mg Orforglipron Capsule QD (Day 9 to Day 22)Cohort 2: 3 mg Orforglipron Capsule QD (Day 23 to Day 36)Cohort 2: 6 mg Orforglipron Capsule QD (Day 37 to Day 50)Cohort 2: 12 mg Orforglipron Capsule QD (Day 51 to Day 64)Cohort 2: 24 mg Orforglipron Capsule QD (Day 65 to Day 78)Cohort 2: 36 mg Orforglipron Capsule QD (Day 79 to Day 92)Cohort 2: Simultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 93)Cohort 2: Simultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin (Day 94)Cohort 2: 36 mg Orforglipron Capsule QD (Day 95 to Day 98)Cohort 2: Staggered 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 99)Cohort 2: 36 mg Orforglipron Capsule (Day 100)Cohort 2: Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin (Day 101)
SchwannomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/300/300/280/280/270/270/270/270/260/260/260/260/260/220/220/220/220/220/220/220/220/210/220/220/200/200/200/200/200/191/190/180/180/160/160/160/160/160/16
Most frequent other events
Showing 10 of 28
Most frequent other events
EventCohort 1: 20 mg Simvastatin Alone (Day 1)Cohort 1: 0.25 mg Digoxin Alone (Day 2)Cohort 1: 20 mg Simvastatin + 600 mg Sodium Bicarbonate (Day 7)Cohort 1: 20 mg Rosuvastatin Alone (Day 8)Cohort 1: 1000 mg Acetaminophen Alone (Day 10)Cohort 1: 0.2 mg Midazolam Alone (Day 12)Cohort 1: Staggered 1 mg Orforglipron Capsule + 1000 mg Acetaminophen (Day 14)Cohort 1: 1 mg Orforglipron Capsule QD (Day 15 to Day 27)Cohort 1: 3 mg Orforglipron Capsule QD (Day 28 to Day 41)Cohort 1: 6 mg Orforglipron Capsule QD (Day 42 to Day 55)Cohort 1: 12 mg Orforglipron Capsule QD (Day 56 to Day 69)Cohort 1: 24 mg Orforglipron Capsule QD (Day 70 to Day 83)Cohort 1: 36 mg Orforglipron Capsule QD (Day 84 to Day 97)Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 98)Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin (Day 99)Cohort 1: 36 mg Orforglipron Capsule QD (Day 100 to Day 103)Cohort 1: Staggered 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 104)Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 20 mg Rosuvastatin (Day 105)Cohort 1: 36 mg Orforglipron Capsule (Day 106)Cohort 1: Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen (Day 107)Cohort 1: 36 mg Orforglipron Capsule (Day 108)Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 0.2 mg Midazolam (Day 109)Cohort 1: 36 mg Orforglipron Capsule (Day 110)Cohort 1: Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin (Day 111)Cohort 2: 20 mg Simvastatin Alone (Day 1)Cohort 2: 0.25 mg Digoxin Alone (Day 2)Cohort 2: Simultaneous 20 mg Simvastatin + 600 mg Sodium Bicarbonate (Day 7)Cohort 2: 1 mg Orforglipron Capsule QD (Day 9 to Day 22)Cohort 2: 3 mg Orforglipron Capsule QD (Day 23 to Day 36)Cohort 2: 6 mg Orforglipron Capsule QD (Day 37 to Day 50)Cohort 2: 12 mg Orforglipron Capsule QD (Day 51 to Day 64)Cohort 2: 24 mg Orforglipron Capsule QD (Day 65 to Day 78)Cohort 2: 36 mg Orforglipron Capsule QD (Day 79 to Day 92)Cohort 2: Simultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 93)Cohort 2: Simultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin (Day 94)Cohort 2: 36 mg Orforglipron Capsule QD (Day 95 to Day 98)Cohort 2: Staggered 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 99)Cohort 2: 36 mg Orforglipron Capsule (Day 100)Cohort 2: Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin (Day 101)
ConstipationGastrointestinal disorders0/300/300/280/280/270/270/270/270/260/260/260/266/260/220/220/220/220/221/220/220/220/210/220/220/200/200/201/201/201/191/191/184/180/161/161/160/160/160/16
FatigueGeneral disorders0/300/300/280/280/270/270/271/271/260/261/260/260/260/220/220/220/220/220/220/220/220/210/220/220/200/200/200/200/203/190/190/181/180/160/160/160/160/160/16
EructationGastrointestinal disorders0/300/300/280/280/270/270/270/270/260/260/260/260/260/220/220/220/220/220/220/220/220/210/220/220/200/200/203/201/202/190/191/180/180/160/160/160/160/160/16
Alanine aminotransferase increasedInvestigations0/300/300/280/280/270/270/270/270/260/261/260/261/260/220/220/220/220/220/220/220/220/210/222/220/200/200/200/201/200/190/190/180/180/160/160/160/160/162/16
Aspartate aminotransferase increasedInvestigations0/300/300/280/280/270/270/270/270/260/261/260/261/260/220/220/220/220/220/220/220/220/210/222/220/200/200/200/201/200/190/190/180/180/160/160/160/160/162/16
NauseaGastrointestinal disorders0/300/300/280/281/270/270/270/271/262/260/260/263/260/222/220/220/220/220/221/220/220/210/220/221/200/200/202/202/201/191/190/181/180/160/160/160/160/160/16
HeadacheNervous system disorders2/300/300/280/280/270/271/270/270/261/260/261/262/260/220/220/220/221/220/221/220/221/210/220/220/200/200/202/200/202/191/190/180/180/160/160/160/160/161/16
Abdominal painGastrointestinal disorders0/300/300/280/280/270/270/270/270/260/260/261/262/260/220/220/220/220/220/220/220/220/210/220/220/200/200/200/202/200/190/190/180/180/160/160/160/160/160/16
Decreased appetiteMetabolism and nutrition disorders0/300/300/280/280/270/270/270/270/260/260/260/260/260/220/220/220/221/220/220/220/220/210/220/220/200/200/202/200/201/190/190/180/180/160/160/160/160/160/16
DyspepsiaGastrointestinal disorders0/300/300/280/280/270/270/270/270/262/260/260/260/260/220/220/220/220/220/220/220/220/210/220/220/200/200/200/200/201/191/190/180/180/160/160/160/160/160/16

Baseline characteristics

All enrolled population.

Age, Continuous
Age, Continuous(Years)Cohort 1: Oral Drug Dosing With or Without OrforglipronCohort 2: Oral Drug Dosing With or Without OrforglipronTotal
Mean45.5 ± 12.8042.9 ± 12.1744.4 ± 12.49
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Oral Drug Dosing With or Without OrforglipronCohort 2: Oral Drug Dosing With or Without OrforglipronTotal
Female211334
Male9716
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Oral Drug Dosing With or Without OrforglipronCohort 2: Oral Drug Dosing With or Without OrforglipronTotal
Hispanic or Latino12719
Not Hispanic or Latino181331
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Oral Drug Dosing With or Without OrforglipronCohort 2: Oral Drug Dosing With or Without OrforglipronTotal
American Indian or Alaska Native112
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American9413
White201535
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Cohort 1: Oral Drug Dosing With or Without OrforglipronCohort 2: Oral Drug Dosing With or Without OrforglipronTotal
United States302050
08

Study locations

2 sites
  • Fortrea Clinical Research Unit Inc.
    Daytona Beach, Florida 32117, United States
  • Fortrea Clinical Research Unit Inc.
    Dallas, Texas 75247, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Jul 2024, 6 months.

Results were first posted in May 2026, 1 year 10 months after primary completion.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 6 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2023
First posted
Jan 2, 2024
StartActual
Jan 2, 2024
Primary completionActual
Jul 10, 2024
CompletionActual
Jul 10, 2024
Results first posted
May 22, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06186622
Responsible party
Sponsor
First posted
Jan 2, 2024
Start date
Jan 2, 2024
Primary completion
Jul 10, 2024
Completion
Jul 10, 2024
Results posted
May 22, 2026
Last update
May 22, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Orforglipron · Simvastatin · Digoxin · Acetaminophen

Start the discussion